Change in Dynamic Hyperinflation After Bronchoscopic Lung Volume Reduction in Patients with Emphysema

Marlies van Dijk1,2 · Karin Klooster1 · Jorine E. Hartman1 · Nick H. T. ten Hacken1 · Dirk-Jan Slebos1

Received: 12 May 2020 / Accepted: 14 July 2020 / Published online: 24 July 2020
© The Author(s) 2020

Abstract
Background and Purpose In patients with severe emphysema, dynamic hyperinflation is superimposed on top of already existing static hyperinflation. Static hyperinflation reduces significantly after bronchoscopic lung volume reduction (BLVR). In this study, we investigated the effect of BLVR compared to standard of care (SoC) on dynamic hyperinflation.
Methods Dynamic hyperinflation was induced by a manually paced tachypnea test (MPT) and was defined by change in inspiratory capacity (IC) measured before and after MPT. Static and dynamic hyperinflation measurements were performed both at baseline and 6 months after BLVR with endobronchial valves or coils (treatment group) or SoC (control group).
Results Eighteen patients underwent BLVR (78% female, 57 (43–67) years, FEV1 25(18–37) %predicted, residual volume 231 (182–376) %predicted). Thirteen patients received SoC (100% female, 59 (44–74) years, FEV1 25 (19–37) %predicted, residual volume 225 (152–279) %predicted. The 6 months median change in dynamic hyperinflation in the treatment group was: + 225 ml (range − 113 to + 803) (p < 0.01) vs 0 ml (− 1067 to + 500) in the control group (p = 0.422). An increase in dynamic hyperinflation was significantly associated with a decrease in residual volume (r = − 0.439, p < 0.01).
Conclusion Bronchoscopic lung volume reduction increases the ability for dynamic hyperinflation in patients with severe emphysema. We propose this is a consequence of improved static hyperinflation.

Keywords COPD · Emphysema · Dynamic hyperinflation · Bronchoscopic lung volume reduction

Introduction
In patients with severe emphysema chronic inflammation results in airway and lung parenchyma damage which is associated with reduced lung elastic recoil and increased airway resistance [1]. The combination of reduced elastic recoil and increased airway resistance can lead to a progressive increase of residual volume (RV) and end-expiratory lung volume (EELV), called static hyperinflation [1]. Increased hyperinflation can lead to dyspnea and consequently to reduced exercise capacity and poor quality of life [2]. Apart from static hyperinflation, exercise can lead to an additional increase in hyperinflation and a further decrease of the inspiratory capacity [1, 2]. This is called dynamic hyperinflation, which is superimposed on top of static hyperinflation. In patients with severe emphysema and severe static hyperinflation bronchoscopic lung volume reduction (BLVR) with endobronchial valves (EBV) or coils can lead to a statistically significant and clinically relevant reduction of static hyperinflation [3]. Furthermore, an improvement of dynamic hyperinflation has been demonstrated in a small group of patients after lung volume reduction surgery [4]. On the other hand, it could also be hypothesized that the improvement of static hyperinflation after bronchoscopic lung volume reduction leads to a larger rest inspiratory capacity (IC), leaving more room for dynamic hyperinflation to occur.

For this study our aim was to investigate if (and if so how) dynamic hyperinflation changed after bronchoscopic lung volume reduction compared to standard of care in patients with severe emphysema and severe static hyperinflation. Additionally, we aimed to investigate if there was
an association between change in dynamic hyperinflation and change in parameters reflecting static hyperinflation and exercise tolerance.

**Methods**

**Study Design and Population**

This was a single-center prospective cohort study in patients with severe emphysema who underwent a bronchoscopic lung volume reduction (BLVR) treatment with either endobronchial valves or coils or standard of care (SoC, no treatment) at the pulmonary department of the University Medical Center Groningen, the Netherlands. All subjects were clinically stable, on optimal medication and had stopped smoking at least 6 months before the study. All subjects participated in one of our bronchoscopic lung volume reduction trials (Clinical trial identifiers: NCT01421082; NCT01101958; NTR2876), which were approved by the local ethics committee. All subjects gave written informed consent. All subjects were included between June 2011 and July 2012. The baseline assessment measurements of this study population were part of an earlier publication [5]. From this baseline cohort patients were randomly invited for follow-up measurements for this study.

**Measurements**

All measurements were performed at baseline and 6 months after BLVR treatment or SoC.

Subjects were instructed to use their regular inhalation medication. An additional 400 µg of salbutamol was administered 15 min before the pulmonary function measurements. Spirometry, body plethysmography and diffusion capacity were measured using the Jaeger MasterScreen™ Body plethysmograph (CareFusion, Germany) and were performed according to the ATS/ERS guidelines using the reference values from the European Community for Coal and Steel [6–8]. The 6-min walk test (6MWT) was performed according to ATS recommendations [9]. The St. George’s Respiratory Questionnaire (SGRQ), and the modified Medical Research Council dyspnea scale (mMRC) were used to measure quality of life and dyspnea severity, respectively [10, 11].

Dynamic hyperinflation was measured using a manually paced tachypnea (MPT) test using the breath-by-breath method (Oxycon Pro™, CareFusion, Germany) during a 15-min protocol (See Fig. 1 for a schematic overview of the MPT procedure) [5]. During tidal breathing the subjects were asked to perform a minimum of 3 slow maximum inspirations (IC maneuver) with 1 min of normal tidal breathing between each maneuver. After this, the technician asked the subject to increase their breathing frequency (BF) to a rate of 40 times per min for 1 min. The technician used a visual real-time registration of the BF and provided the subject with vocal feedback of their BF. After 1 min of tachypnea, the subjects immediately performed an IC maneuver. The MPT procedure was repeated at least 3 times, with 3 min of normal tidal breathing between maneuvers. To establish the baseline IC (ICbaseline), we calculated the mean value of 3 reproducible IC’s (within 150 ml). To establish the IC post tachypnea (ICMPT) we calculated the mean value of the 2 highest and reproducible IC’s (within 150 ml).

**Statistics**

Power was calculated based on mean change in IC of 0.5L (SD 0.4) [12]. With a power of 0.80 and alpha of 0.05 at least 12 patients per group needed to be included. Data was calculated as median (minimum–maximum) unless indicated otherwise. Dynamic hyperinflation was calculated by the absolute change in IC (ICMPT minus ICbaseline). A negative value of the absolute change in IC indicates a greater amount of dynamic hyperinflation.

A Mann–Whitney U test was performed to compare baseline and follow-up lung function parameters, SGRQ and 6MWD. A Wilcoxon signed rank test was used to compare baseline characteristics, change in lung function parameters, SGRQ and 6MWD between groups (BLVR vs. SoC).

![Fig. 1 Schematic overview of the dynamic hyperinflation measurement. IC inspiratory capacity, MPT manually paced tachypnea, f frequency (40 times/min). Image reprinted with permission of respiration [5]](image-url)
A Spearman correlation coefficient was calculated to assess the association between change in dynamic hyperinflation and change in static hyperinflation, airflow obstruction and 6-min walk distance. A p-value of < 0.05 was considered statistically significant. IBM SPSS Statistics version 23 (IBM, Armonk, NY, USA) was used for all analyses.

Results

We studied 31 clinically stable patients with severe emphysema. Thirteen patients received SoC (100% female, 59 (44–74) years, FEV1 25 (19–37) %predicted, residual volume 225 (152–279) %predicted. Eighteen patients underwent BLVR (78% female, 57 (43–67) years, FEV1 25(18–37) %predicted, residual volume 231 (182–376) %predicted. Of these, ten patients were treated with coils, eight patients received endobronchial valves. There were no statistically significant differences in baseline characteristics between the control and treatment group (Table 1).

Dynamic hyperinflation changed significantly with −225 ml (−803 to +113) (p < 0.01) 6 months after BLVR. In the group of subjects receiving SoC, there was no significant change in dynamic hyperinflation (0 ml, range −1067 to +500). See Fig. 2 for individual outcomes. There were no statistically significant differences in change in dynamic hyperinflation measured by a man–machine paced tachypnea test after lung volume reduction treatment [4, 12, 14, 15]. However, it is difficult to compare these studies to our own results because there are some important differences. First of all, different techniques were used, i.e., measurement of inspiratory capacity during rest and cardiopulmonary exercise testing (CPET) [4, 12, 14] and optoelectronic plethysmography [15].

Secondly, the breathing frequency was lower in the other studies compared to this study (25–28 times/min versus 40 times/min). And, perhaps most importantly, different definitions for dynamic hyperinflation were used. We defined dynamic hyperinflation as the change in inspiratory capacity after a period of tachypnea compared to resting breathing frequency. However, if end-expiratory lung volume at the end of the test is used to define dynamic hyperinflation, this may lead to a different outcome, because this value is also influenced by a change in static hyperinflation. Severity of airflow obstruction and static hyperinflation were comparable to our subjects in all studies.

In this single-center prospective cohort study, we investigated change in dynamic hyperinflation measured by a manually paced tachypnea test after lung volume reduction treatment with either endobronchial valves or coils compared to standard of care. We demonstrated a significant increase in dynamic hyperinflation after BLVR, which was not the case for standard of care. Change in dynamic hyperinflation showed a significant inverse association with change in residual volume and a significant association with change in IC/TLC ratio and change in 6-min walk distance.

Contrary to our results, several other studies have demonstrated a reduction of dynamic hyperinflation after lung volume reduction treatment [4, 12, 14, 15]. However, it is difficult to compare these studies to our own results because there are some important differences. First of all, different techniques were used, i.e., measurement of inspiratory capacity during rest and cardiopulmonary exercise testing (CPET) [4, 12, 14] and optoelectronic plethysmography [15].

On a group level there was no change in dynamic hyperinflation in the control group after 6 months of standard of care. However, as shown in Fig. 2, on an individual level there were large variations in dynamic hyperinflation at baseline and follow-up. We propose that this is a reflection of real-life variability of dynamic hyperinflation in patients with COPD, most likely caused by changes in small airways disease such as mucus impaction and airway wall edema.
However, variability in the procedure can also play a role. Lahaije et al. found a repeatability coefficient of 8.5% for the MPT in patients with moderate COPD [16].

If dynamic hyperinflation increases after bronchoscopic lung volume reduction, does this have therapeutic consequences? We believe the most important message is to reinforce adequate breathing techniques in our patients, focusing on slow, deep breaths during exercise. A meta-analysis showed that long-acting bronchodilators did have an effect on EELV during exercise, but this was a consequence of an improved IC in rest (i.e., reduction in static hyperinflation) [17]. Interestingly, O’Donnel and colleagues demonstrated a protective effect of dynamic hyperinflation at lower exercise intensities by attenuation of the expiratory flow [18].

Our study does have some limitations. The group of subjects was relatively small. Especially since our results relating to dynamic hyperinflation are different from earlier studies, it would be interesting to investigate the change in dynamic hyperinflation by MPT in another, larger cohort of patients with COPD who undergo bronchoscopic lung

### Table 1: Baseline characteristics

| Baseline characteristic | Treatment group | Control group | p-value |
|-------------------------|-----------------|---------------|---------|
|                         | n = 18          | n = 13        |         |
| Female—no. (%)          | 14 (78%)        | 13 (100%)     | 0.073   |
| Age—year                | 57 (43 to 67)   | 59 (44 to 74) | 0.40    |
| Body-mass index—kg/m²   | 23 (16 to 29)   | 22 (18 to 26) | 0.32    |
| Cigarette smoking—no. of pack years | 38 (5 to 80) | 40 (23 to 110) | 0.95 |
| **FEV**₁ Liters         | 0.63 (0.45 to 1.01) | 0.69 (0.40 to 0.87) | 0.33 |
| % of predicted          | 25 (18 to 37)   | 25 (19 to 37) | 0.56    |
| **FVC** Liters          | 2.38 (1.28 to 3.71) | 2.01 (1.08 to 2.92) | 0.11 |
| % of predicted          | 70 (44 to 101)  | 63 (50 to 113) | 0.48    |
| **RV** Liters           | 4.87 (2.93 to 7.71) | 4.10 (3.09 to 5.58) | 0.11 |
| % of predicted          | 231 (182 to 376) | 225 (152 to 279) | 0.24    |
| **TLC** Liters          | 7.48 (5.75 to 10.76) | 6.83 (5.27 to 7.92) | 0.08 |
| % of predicted          | 134 (120 to 183) | 135 (114 to 150) | 0.56    |
| **RV**/**TLC**—%        | 65 (48 to 74)   | 65 (52 to 75)  | 0.97    |
| **IC**/**TLC**—%        | 20 (16 to 38)   | 24 (16 to 37)  | 0.38    |
| **RAW** kPa*S/L         | 0.76 (0.33 to 1.21) | 0.67 (0.47 to 1.00) | 0.98 |
| % of predicted          | 252 (109 to 404) | 225 (158 to 334) | 0.98    |
| Dynamic hyperinflation—ml | −610 (−1240 to −120) | −608 (−1260 to −260) | 0.90 |
| Carbon monoxide diffusing capacity mmol/(min*kPa) | 3.12 (1.93 to 5.52) | 2.76 (1.05 to 4.35) | 0.37 |
| % of predicted          | 32 (24 to 69)   | 35 (14 to 57)  | 0.96    |
| Arterial blood gas (on room air)— kPa |                  |               |         |
| **PaO**₂                | 9.2 (7.1 to 11.9) | 8.5 (7.6 to 12.6) | 0.32    |
| **PaCO**₂               | 5.4 (4.4 to 6.9)  | 5.2 (4.2 to 6.6) | 0.41    |
| 6-min walk test         |                |               |         |
| Distance—meters         | 318 (160 to 485) | 400 (160 to 459) | 0.17    |
| Questionnaires          |                |               |         |
| **SGRQ** total score—points | 60 (25 to 79) | 59 (43 to 89) | 0.75 |
| mMRC—points             | 3 (1 to 4)      | 3 (2 to 4)     | 0.83    |

Data is represented as median (min to max) or number (%)

There were no statistically significant differences between the treatment group and control group (Mann–Whitney U test).

**FEV**₁ forced expiratory volume in 1 s, **FVC** forced vital capacity, **RV** residual volume, **TLC** total lung capacity, **RAW** airway resistance, **SGRQ** St George Respiratory Questionnaire, **CCQ** Clinical COPD Questionnaire.
Table 2 Median change in lung function, dynamic hyperinflation, 6MWD and SGRQ 6 months after BLVR treatment (n = 18) or SoC (n = 13)

|                           | BLVR treatment (n = 18) | Standard of care (n = 13) | BLVR vs. SoC p-value |
|---------------------------|-------------------------|---------------------------|----------------------|
| ΔDH ml                    | -225 (−803 to +113)*    | 0 (−500 to +1067)         | 0.002                |
| Relative change (%) ml    | -33 (−186 to +15)       | 0 (−128 to +988)          | 0.034                |
| ΔFEV₁ ml                  | +110 (−130 to +770)*    | +20 (−10 to +13)          | 0.010                |
| Relative change (%) ml    | +22 (−16 to +76)        | +3 (−13 to 17)            |                      |
| ΔIC (rest) ml             | -200 (−350 to +1530)*   | -33 (−430 to +270)        | <0.001               |
| Relative change (%) ml    | +11 (−12 to +70)        | -2 (−23 to +15)           |                      |
| ΔRV ml                    | -765 (−3010 to +40) *   | +40 (−140 to +280)        |                      |
| Relative change (%) ml    | -15 (−39 to +1)         | +1 (−3 to 7)              |                      |
| ΔTLC ml                   | -295 (−690 to +230) *   | +40 (−290 to +260)        | 0.002                |
| Relative change (%) ml    | -295 (−690 to +230)     | +0.6 (−3.7 to +3.7)       |                      |
| ΔRatio of RV to TLC-%     | -8 (−25 to +1)*         | +0 (−2 to +4)             | <0.001               |
| ΔRatio of IC to TLC-%     | +3 (−3 to +20)          | -1 (−7 to +4)             | 0.006                |
| ΔRaw (kPa*S/L)            | -0.14 (−0.48 to +0.29)* | 0.01 (−0.15 to +0.29)     | 0.06                 |
| Δ6MWD meters              | +55 (−8 to +233) *      | -17 (−134 to +53)         | <0.001               |
| ΔSGRQ points              | -11 (−53 to +6)         | -1 (−25 to +9)            | 0.020                |

All changes between baseline and follow-up were statistically significant for the treatment group, *p < 0.05. There were no statistically significant changes between baseline and follow-up for the SoC group measured by Mann–Whitney U test.

BLVR bronchoscopic lung volume reduction, DH dynamic hyperinflation, FEV₁ forced expiratory volume in 1 s, IC inspiratory capacity, RV residual volume, TLC total lung capacity, Raw airway resistance, 6MWD 6-min walk distance, SGRQ St Georges Respiratory Questionnaire.
volume reduction. Furthermore, the MPT test induces dynamic hyperinflation through tachypnea, but does not require exercise which is usually the trigger for DH to develop in patients with COPD. Excessive mechanical loading, ventilation of physiological dead space, arterial hypoxemia and early metabolic acidosis due to skeletal muscle deconditioning can lead to increased inspiratory neural drive to the respiratory muscles during exercise in COPD patients [19]. Furthermore, testing DH with CPET provides additional information on the influence of DH on exercise-induced dyspnea, cardiovascular function and muscle function [20]. A future study using both MPT and CPET to investigate change in dynamic hyperinflation would therefore be interesting.

**Conclusion**

In our population of patients with severe emphysema, we found that dynamic hyperinflation increases after bronchoscopic lung volume reduction with coils or endobronchial valves, while static hyperinflation significantly improves. No significant changes were seen in the standard of care group. We propose that the underlying mechanism for this is that bronchoscopic lung volume reduction treatment improves static hyperinflation and therefore increases the ability for dynamic hyperinflation to occur in patients with severe emphysema.

**Acknowledgements** The authors would like to thank the pulmonary function technicians Marga Star, Yvonne Valkema, Maria Heuving and Margrietha Swierenga for their dedicated testing and Martijn Farenhorst for his technical support. Ruth Hiltermann for performing the 6-min walk tests and obtaining questionnaires.

**Funding** No funding was received for this investigation.

**Data Availability** The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

**Compliance with Ethical Standards**

**Conflict of interest** DJS is an advisor and investigator for PulmonX, CA, USA and PneumRx/PTG CA/USA. MD, KK, JH and NiH have no conflicts of interest.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
References

1. Cooper CB (2009) Airflow obstruction and exercise. Respir Med 103(3):325–334. https://doi.org/10.1016/j.rmed.2008.10.026

2. Cooper CB (2006) The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 119(10 Suppl 1):21–31. https://doi.org/10.1016/j.amjmed.2006.08.004

3. van Geffen WH, Slebos DJ, Herfst FH, Kemp SV, Weder W, Shah PL (2019) Surgical and endoscopic interventions that reduce lung volume for emphysema: a systemic review and meta-analysis. Lancet Respir Med 7(4):313–324. https://doi.org/10.1016/S2213-2600(18)30431-4

4. Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR (2005) Standards of spirometry. Eur Respir J 26(2):319–338. https://doi.org/10.1183/09031936.05.00034805

5. Klooster K, ten Hacken NH, Hartman JE, Sciruba FC, Kerstjens HA, Slebos DJ (2015) Determining the role of dynamic hyperinflation in patients with severe chronic obstructive pulmonary disease. Respiration 90(4):306–313. https://doi.org/10.1159/000439056

6. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J, Force AET (2005) Standardisation of spirometry. Eur Respir J 26(2):319–338. https://doi.org/10.1183/09031936.05.00034805

7. Wanger J, Clausen JL, Coates A, Pedersen OF, Brusasco V, Burgos F, Casaburi R, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pellegrino R, Viegi G (2005) Standardisation of the measurement of lung volumes. Eur Respir J 26(3):511–522. https://doi.org/10.1183/09031936.05.00035005

8. Stocks J, Quanjer PH (1995) Reference values for residual volume, functional residual capacity and total lung capacity. ATS workshop on lung volume measurements. Official statement of the European Respiratory Society. Eur Respir J 8(3):492–506. https://doi.org/10.1183/09031936.95.08030492

9. Laboratories ATSCoPSfCPF (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166(1):111–117. https://doi.org/10.1164/ajrccm.166.1.at1102

10. Jones PW, Quirk FH, Baveystock CM, Littlejohns P (1992) A self-complete measure of health status for chronic airflow limitation. The St. George’s Respiratory Questionnaire. Am Rev Respir Dis 145(6):1321–1327. https://doi.org/10.1164/ajrccm/145.6.1321

11. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA (1999) Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54(7):581–586. https://doi.org/10.1136/thx.54.7.581

12. Hopkinson NS, Toma TP, Hansell DM, Goldstraw P, Moxham J, Geddes DM, Polkey MI (2005) Effect of bronchoscopic lung volume reduction on dynamic hyperinflation and exercise in emphysema. Am J Respir Crit Care Med 171(5):453–460. https://doi.org/10.1164/rcrccm.200407-9610C

13. O’Donnell DE, Laveneziana P (2007) Dyspnea and activity limitation in COPD: mechanical factors. COPD 4(3):225–236. https://doi.org/10.1080/15412550701480455

14. Makris D, Leroy S, Pradelli J, Benzaquen J, Guenard H, Perotin JM, Zakynthinos S, Zakynthinos E, Deslee G, Marquette CH (2018) Changes in dynamic lung mechanics after lung volume reduction coil treatment of severe emphysema. Thorax 73(6):584–586. https://doi.org/10.1136/thoraxjnl-2017-210118

15. Layton AM, Armstrong HF, Moran SL, Guenette JA, Thomashow BM, Jellen PA, Bartels MN, Sheel AW, Basner RC (2015) Quantification of improvements in static and dynamic ventilatory measures following lung volume reduction surgery for severe COPD. Chronic Obstr Pulm Dis 2(1):61–69. https://doi.org/10.15326/jcopdf.2.1.2014.0145

16. Lahajie AJ, Willems LM, van Hees HW, Dekhuijzen PN, van Helvoort HA, Heijdra YF (2013) Diagnostic accuracy of metronome-paced tachypnea to detect dynamic hyperinflation. Clin Physiol Funct Imaging 33(1):62–69. https://doi.org/10.1111/j.1475-097X.2012.01164.x

17. Di Marco F, Sotgiu G, Santus P, O’Donnell DE, Beeh KM, Dore S, Roggi MA, Giuliani L, Blasi F, Centanni S (2018) Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis. Respir Res 19(1):18. https://doi.org/10.1186/s12931-018-0721-3

18. O’Donnell DE, Hamilton AL, Webb KA (2006) Sensory-mechanical relationships during high-intensity, constant-work-rate exercise in COPD. J Appl Physiol 101(4):1025–1035. https://doi.org/10.1152/japplphysiol.01470.2005

19. O’Donnell DE, Elbehairy AF, Webb KA, Neder JA, Canadian Respiratory Research N (2017) The link between reduced inspiratory capacity and exercise intolerance in chronic obstructive pulmonary disease. Ann Am Thorac Soc 14(Supplement_1):S30–S39. https://doi.org/10.1513/AnnalsATS.201610-834PR

20. Langer D, Ciavaglia CE, Neder JA, Webb KA, O’Donnell DE (2014) Lung hyperinflation in chronic obstructive pulmonary disease: mechanisms, clinical implications and treatment. Expert Rev Respir Med 8(6):731–749. https://doi.org/10.1080/1747348.2014.949676

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.